再生元製藥公司 REGN 深 滬
已收盤 10-31 16:00:00 美东时间
651.80
-2.240
-0.34%
華盛通- 最 高660.00
- 今 開649.45
- 成交量 79.80万股
- 最 低 645.00
- 昨 收 654.04
- 總市值 703.94亿
- 52周最高 831.78
- 市盈率 靜 17.00
- 換手率 0.74%
- 52周最低 475.6069
- 委 比 -35.48%
- 總股本 1.08亿
- 歷史最高 1208.5599
- 量 比 0.56
- 振 幅 2.29%
- 歷史最低 40.19
- 每 手 1
- 風險率 85.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Insider Moves: Blackstone, Regeneron, Schwab, Celestica, Corning
Insiders have been trading these 5 stocks: (($BX)), (($REGN)), (($SCHW)), (($TS...
11-01 21:00
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
<p>Dupixent, developed by Regeneron, has been awarded the 2025 "Best Biotechnology Product" by the Galien Foundation. It is the first and only therapy targeting the IL-4 and IL-13 signaling pathway, key drivers of type 2 inflammation. Dupixent is approved for eight conditions, including atopic dermatitis, asthma, and COPD, and has helped over 1 million patients globally. The therapy's innovative approach redefines understanding of allergic and at...
10-31 11:00
Regeneron’s New Study Targets Improved Outcomes in Multiple Myeloma
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinic...
10-31 00:30
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinic...
10-30 00:30
Regeneron Pharmaceuticals declares $0.88 dividend
Regeneron Pharmaceuticals (REGN) declares $0.88/share quarterly dividend, in line with previous. Forward yield 0.54% Payable Dec. 5; for shareholders of record Nov. 20; ex-div Nov. 20. See REGN Divide...
10-29 22:17
Uncovering Potential: Alnylam Pharmaceuticals's Earnings Preview
Alnylam Pharmaceuticals (NASDAQ:ALNY) is gearing up to announce its quarterly e...
10-29 22:04
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $865
Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $815 to $865.
10-29 20:46
1410亿身家！“医药女王”钟慧娟携女登顶“中国女首富”！
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源 | 野马财经 作者 | 孙梦圆 赵普 刘钦文 “中...
10-29 18:57
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
<p>ModeX Therapeutics and Regeneron Pharmaceuticals have entered into a collaboration to develop multispecific antibodies targeting multiple disease pathways. ModeX will receive USD $7 million upfront, plus potential milestone and royalty payments exceeding USD $200 million per molecule, with a potential total value over $1 billion. The MSTAR platform will be used to create innovative antibody candidates for indications like immunology, oncology,...
10-29 12:00
